The advances in technology over the past decade have yielded a broad range of biologics for cancer, each with unique attributes. This is great news for patients to have so many tools in the toolkit, but challenging for drug developers, and even for oncologists making treatment decisions. Today more than ever, the environment, whether prospective funders or partners, is much less forgiving of missteps in understanding the value proposition for each of these unique therapeutic modalities that are shaping the future standard of care for cancer. This session will hear from panelists as they engage in a clearsighted dialogue around the strengths, weaknesses, challenges, and opportunities of these various approaches as they highlight some of the key learnings in charting a course for the current and next generation of early-stage innovative modalities.